66411-22-1

Usage

Uses

Used in Pharmaceutical Industry:
8-Amino-2,3-dihydrobenzo[1,4]dioxine-5-carboxylic acid is used as a building block for the synthesis of various pharmaceutical compounds and other biologically active molecules. Its chemical properties contribute to the development of drugs and other compounds with medicinal properties.
Used in Organic Synthesis:
8-Amino-2,3-dihydrobenzo[1,4]dioxine-5-carboxylic acid is used as an intermediate in the production of compounds with therapeutic uses, thanks to its unique structure and reactivity.
Used in Research and Development:
8-Amino-2,3-dihydrobenzo[1,4]dioxine-5-carboxylic acid has potential applications in the research and development of new chemical compounds with therapeutic uses, given its potential to be a key component in the synthesis of novel pharmaceuticals.

InChI:InChI=1/C9H9NO4/c10-6-2-1-5(9(11)12)7-8(6)14-4-3-13-7/h1-2H,3-4,10H2,(H,11,12)

Upstream product

• 66411-17-4 6,7-dibromo-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxylic acid 
• 4442-53-9 2,3-dihydro-1,4-benzodioxine-5-carboxylic acid 
• 66411-18-5 6,7-dibromo-8-nitro-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxylic acid 

Downstream Products

• 191024-16-5 ethyl 8-amino-2,3-dihydro-1,4-benzodioxine-5-carboxylate 
• 158504-37-1 methyl 8-amino-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxylate 
• 148703-26-8 8-amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid 

Relevant academic research and scientific papers

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

Pilot scale process development of SL65.0102-10, an N-diazabicyclo[2.2.2]-octylmethyl Benzamide

The process development and improvements for route selection, adapted to large scale for the pilot-scale preparation of SL65.0102-10, an N-diazabicyclo[2.2.2]-octylmethyl benzamide, a 5-HT3 and 5-HT4 receptor active ligand for the treatment of neurological disorders such as cognition impairment, are described in this article. Notable steps and enhancements are compared to the original route, including the improvement of a chiral epoxide synthesis by shortening the number of chemical steps, the deprotection of a quaternary ammonium salt, and the redesign of the final amidification coupling to avoid chromatography.

2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE

Specific Compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein m, X, R, R2, R3, R, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Substituted 2,3-alkylene bis (oxy) benzamides and derivatives and method of preparation

Novel substituted 2,3-alkylene bis (oxy) benzamides and derivatives thereof are disclosed. Also disclosed is a method for producing said compounds. The compounds have anxiolytic, psychostimulant, disinhibiting and thymoanaleptic properties useful therapeutically in the psychofunctional field, particularly in gastro-enterology, cardiology, urology, rheumatology and gynaecology.